Seattle Genetics, Inc. (NASDAQ:SGEN) EVP Darren S. Cline sold 1,788 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $47.89, for a total value of $85,627.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Darren S. Cline also recently made the following trade(s):

  • On Monday, August 7th, Darren S. Cline sold 6,000 shares of Seattle Genetics stock. The shares were sold at an average price of $49.19, for a total value of $295,140.00.

Seattle Genetics, Inc. (NASDAQ:SGEN) opened at 52.55 on Friday. The company’s market capitalization is $7.52 billion. Seattle Genetics, Inc. has a 52 week low of $44.45 and a 52 week high of $75.36. The stock’s 50 day moving average is $49.99 and its 200 day moving average is $59.90.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. The firm had revenue of $108.20 million during the quarter, compared to the consensus estimate of $105.92 million. Seattle Genetics had a negative return on equity of 32.87% and a negative net margin of 47.38%. The company’s quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.23) earnings per share. Analysts predict that Seattle Genetics, Inc. will post ($1.69) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/02/seattle-genetics-inc-sgen-evp-sells-85627-32-in-stock.html.

SGEN has been the subject of a number of recent analyst reports. Cann reaffirmed a “hold” rating on shares of Seattle Genetics in a research note on Tuesday. J P Morgan Chase & Co reissued a “hold” rating and set a $58.00 target price on shares of Seattle Genetics in a research note on Tuesday, June 13th. Cantor Fitzgerald reissued a “hold” rating and set a $43.00 target price on shares of Seattle Genetics in a research note on Monday, June 26th. Piper Jaffray Companies reissued a “neutral” rating and set a $48.00 target price on shares of Seattle Genetics in a research note on Tuesday, June 27th. Finally, Cowen and Company set a $61.00 target price on Seattle Genetics and gave the stock a “hold” rating in a research note on Tuesday, June 6th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $62.29.

Several large investors have recently added to or reduced their stakes in SGEN. Bank of Montreal Can increased its stake in Seattle Genetics by 280.2% in the first quarter. Bank of Montreal Can now owns 7,235 shares of the biotechnology company’s stock valued at $454,000 after buying an additional 5,332 shares in the last quarter. Capstone Asset Management Co. increased its stake in Seattle Genetics by 7.4% in the first quarter. Capstone Asset Management Co. now owns 5,055 shares of the biotechnology company’s stock valued at $318,000 after buying an additional 350 shares in the last quarter. Nationwide Fund Advisors purchased a new stake in Seattle Genetics during the first quarter valued at approximately $1,402,000. Shell Asset Management Co. increased its stake in Seattle Genetics by 5.2% in the first quarter. Shell Asset Management Co. now owns 24,961 shares of the biotechnology company’s stock valued at $1,569,000 after buying an additional 1,230 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Seattle Genetics during the first quarter valued at approximately $119,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.